Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen

NCT00038467 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00038467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00038467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
February 28, 1998
Completion date
March 31, 2013
Enrollment
4,740 (actual)
Sites
377

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms